Update from Genzyme on Acid Sphingomyelinase Deficiency (ASMD) Development Efforts

Dear Friends and Families,

Genzyme, a Sanofi company, is pleased to update the Niemann-Pick disease patient community on the progress of efforts to develop a potential therapy for acid sphingomyelinase deficiency (ASMD, also known as Niemann-Pick disease Types A and B).

Visit the Enzyme Replacement Therapy Page for the full Press Release.